Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys, Inc. reported developments tied to its home health, hospice and high-acuity care in the home operations and to its public-company status. Company updates covered operating and financial results, material agreements, capital-structure matters, and care delivery programs, including Contessa Health’s participation in a CMS dementia care payment model and recognition of home health and hospice care centers for patient and caregiver satisfaction.
In August 2025, Amedisys became a wholly owned subsidiary of UnitedHealth Group following a completed merger. The completed transaction changed Amedisys from a Nasdaq-listed operating company into a subsidiary, making corporate-status and capital-structure updates part of the company’s durable news record.
Amedisys, Inc. (NASDAQ: AMED) announced a Care Coordination Agreement with BrightStar Care, integrating their personal care agencies into the Amedisys Personal Care Network. This partnership aims to enhance care coordination between Amedisys' hospice and home health centers, reaching approximately 75% of the U.S. population through BrightStar's 340 locations across 38 states. The pilot program will start in Pennsylvania and Texas, focusing on reducing hospital admissions by effectively managing patients with chronic conditions.
Amedisys, Inc. (NASDAQ: AMED) reported Q2 2020 net service revenue of $485 million, down $8 million from $493 million in 2019. Net income increased to $34.7 million ($1.04 per diluted share) from $33.7 million ($1.02) year-over-year. Year-to-date revenue rose to $976.7 million, with net income of $66.5 million ($2.00 per diluted share), up from $65 million ($1.98). The company reaffirmed its 2020 guidance, anticipating annual net revenue between $2.040 billion and $2.070 billion and adjusted EBITDA of $245 million to $255 million. CEO Paul B. Kusserow highlighted company resilience during the COVID-19 pandemic.
Amedisys, Inc. (NASDAQ: AMED) will report its Q2 results for the period ending June 30, 2020, after market close on July 28, 2020. An investor conference call will be held the next day, July 29, 2020, at 11:00 a.m. ET to discuss these results. Participants can join via telephone or listen to a live webcast on the company’s Investor Relations page. Amedisys is a leader in healthcare at home, offering personalized home health, hospice, and personal care to over 415,000 patients annually, with a workforce of 21,000 across 526 care centers in 39 states.
Amedisys, Inc. (NASDAQ: AMED) announced that its President and CEO, Paul B. Kusserow, will present at the 2020 BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 p.m. Eastern Time. Amedisys, a leading home health, hospice, and personal care company, emphasizes personalized care and has partnerships with over 2,600 hospitals and 67,000 physicians. The company serves more than 415,000 patients annually across 39 states and the District of Columbia, employing 22,000 staff in 524 care centers.
Amedisys, a leading home health and hospice company, announced that CEO Paul B. Kusserow will present at the 40th Annual William Blair Growth Stock Conference on June 10, 2020, at 3:00 p.m. Eastern Time. Investors can access the live webcast on the company’s website. Amedisys operates across 39 states, providing personalized care to over 415,000 patients annually. With 22,000 employees and 524 care centers, the company partners with over 2,600 hospitals and 67,000 physicians nationwide, focusing on delivering high-quality home-based healthcare.
Amedisys (NASDAQ: AMED) has completed its acquisition of AseraCare Hospice for $235 million, with a net purchase price of $203 million after accounting for a $32 million tax asset. This acquisition expands Amedisys' hospice services, increasing their care centers to 190 across 35 states and serving approximately 14,000 patients daily. AseraCare, with annual revenues of around $117 million, has 44 locations and employs over 1,200 hospice professionals. Amedisys aims to enhance patient care and reach more communities with this strategic move.
Amedisys, a leading home health and hospice provider, announced that CEO Paul B. Kusserow will present at the 2020 Jefferies Virtual Healthcare Conference on June 2, 2020, at 11:00 a.m. Eastern Time. The presentation can be accessed via a live webcast on Amedisys' investor relations website. Founded in 1982, Amedisys focuses on delivering personalized care to patients across 38 states and the District of Columbia, partnering with over 2,600 hospitals and 67,000 physicians nationwide to provide high-quality home-based care.
Amedisys, Inc. (NASDAQ: AMED) announced that CEO Paul B. Kusserow will present at the RBC Capital Markets 2020 Global Healthcare Conference on May 19, 2020, at 1:20 p.m. ET. Investors can access the live webcast through Amedisys’ website.
Founded in 1982 and headquartered in Baton Rouge, LA, Amedisys is a leading provider of home health, hospice, and personal care services, serving over 415,000 patients annually with a workforce of more than 21,000 employees across 480 care centers in 38 states and the District of Columbia.
Amedisys, Inc. (NASDAQ: AMED) will be presenting at the UBS Global Healthcare Conference 2020 on May 18, 2020, at 3:00 p.m. Eastern Time. Paul B. Kusserow, the President and CEO, will lead the presentation. Investors can access the live webcast on the Amedisys investor relations website. Amedisys is recognized for its home health, hospice, and personal care services, ensuring quality care for over 415,000 patients annually. The company operates 480 care centers across 38 states and the District of Columbia.
Amedisys, Inc. (NASDAQ: AMED) reported a net service revenue of $491.7 million for Q1 2020, an increase of $24.4 million from 2019. Net income rose to $31.8 million, with earnings per share at $0.96. However, adjusted EBITDA decreased to $53.3 million from $54.9 million in 2019. Due to the ongoing COVID-19 pandemic, the company has withdrawn its full-year guidance, citing uncertainty in its financial outlook. Amedisys emphasizes the resilience of its business model and commitment to quality care.